Literature DB >> 17219030

News on the genetics, epidemiology, medical care and translational research of Schwannomas.

C O Hanemann1, D G Evans.   

Abstract

Recent years have seen substantial news and updates in the genetics and diagnosis of schwannomas, even a new hereditary disease with schwannomas; Schwannomatosis has been defined. These developments have consequently led to better evaluation of the incidence of schwannomas. Although there has also been progress in the treatment of schwannomas especially in the field of radiation therapy, hereditary diseases with multiple tumours still represent a therapeutic dilemma. NF2 in particular still causes major morbidity and mortality owing to the neurological deficit of multiple tumour disease and deafness caused by vestibular nerve involvement. Thus there has been great enthusiasm about disease models in the hope that translational research will give rise to new therapies.

Entities:  

Mesh:

Year:  2006        PMID: 17219030     DOI: 10.1007/s00415-006-0347-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  63 in total

1.  Exploring the "two-hit hypothesis" in NF2: tests of two-hit and three-hit models of vestibular schwannoma development.

Authors:  Ryan Woods; J M Friedman; D Gareth R Evans; Michael E Baser; Harry Joe
Journal:  Genet Epidemiol       Date:  2003-05       Impact factor: 2.135

2.  Incidence of vestibular schwannomas.

Authors:  M Tos; S Charabi; J Thomsen
Journal:  Laryngoscope       Date:  1999-05       Impact factor: 3.325

3.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

4.  Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.

Authors:  Shanta M Messerli; Shilpa Prabhakar; Yi Tang; Umar Mahmood; Marco Giovannini; Ralph Weissleder; Rodrick Bronson; Robert Martuza; Samuel Rabkin; Xandra O Breakefield
Journal:  Hum Gene Ther       Date:  2006-01       Impact factor: 5.695

5.  Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling.

Authors:  Daniel R Scoles; Vu D Nguyen; Yun Qin; Chun-Xiao Sun; Helen Morrison; David H Gutmann; Stefan-M Pulst
Journal:  Hum Mol Genet       Date:  2002-12-01       Impact factor: 6.150

6.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

7.  Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety.

Authors:  V F Mautner; M Tatagiba; M Lindenau; C Fünsterer; S M Pulst; M E Baser; L Kluwe; F E Zanella
Journal:  AJR Am J Roentgenol       Date:  1995-10       Impact factor: 3.959

8.  Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.

Authors:  C Warren; L A James; R T Ramsden; A Wallace; M E Baser; J M Varley; D G Evans
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

9.  Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.

Authors:  Joseph L Kissil; Erik W Wilker; Kristen C Johnson; Matthew S Eckman; Michael B Yaffe; Tyler Jacks
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

10.  Neurofibromatosis 2, radiosurgery and malignant nervous system tumours.

Authors:  M E Baser; D G Evans; R K Jackler; E Sujansky; A Rubenstein
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  12 in total

Review 1.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

2.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

Review 3.  Merlin, the NF2 gene product.

Authors:  Nives Pećina-Šlaus
Journal:  Pathol Oncol Res       Date:  2013-05-12       Impact factor: 3.201

4.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Joceline Triner; Paul Manley; Clemens Oliver Hanemann
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

5.  A clinicopathological study of peripheral schwannomas.

Authors:  Ankur Majumder; Arvind Ahuja; D S Chauhan; Purnima Paliwal; Minakshi Bhardwaj
Journal:  Med Pharm Rep       Date:  2021-04-29

6.  Recurrent orbital schwannomas: clinical course and histopathologic correlation.

Authors:  Michelle Kron; Brenda L Bohnsack; Steven M Archer; Jonathan B McHugh; Alon Kahana
Journal:  BMC Ophthalmol       Date:  2012-08-31       Impact factor: 2.209

7.  Schwannoma of the vagina - a common tumor but a rare location: A case report.

Authors:  Xin An; Meng Zhu; Ning Zhang; Sanjun Lu; Pin Wei; Linna Jiang; Xueli Yang
Journal:  Mol Clin Oncol       Date:  2017-09-19

8.  Primary recurrent orbital schwannoma treated with surgical excision and Mitomycin-C.

Authors:  Kai Ching Peter Leung; Nerissa Kei Yen Lam; Edwin Chan; Tak Chuen Simon Ko
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-15

Review 9.  Why are olfactory ensheathing cell tumors so rare?

Authors:  James A St John; Jenny A K Ekberg; Mariyam Murtaza; Anu Chacko; Ali Delbaz; Ronak Reshamwala; Andrew Rayfield; Brent McMonagle
Journal:  Cancer Cell Int       Date:  2019-10-11       Impact factor: 5.722

10.  Frequency of loss of heterozygosity of the NF2 gene in schwannomas from Croatian patients.

Authors:  Nives Pećina-Slaus; Martina Zeljko; Hrvoje Ivan Pećina; Tamara Nikuseva Martić; Niko Bacić; Davor Tomas; Reno Hrasćan
Journal:  Croat Med J       Date:  2012-08       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.